HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer

Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) resistance remains a therapeutic challenge in ovarian cancer. High-mobility group box 3 (HMGB3) plays significant roles in the development of drug resistance of many cancers. However, the function of HMGB3 in PARPi resistance is poorly understood...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hanlin, Qi, Gonghua, Han, Fang, Lu, Wei, Peng, Jiali, Li, Rongrong, Yan, Shi, Yuan, Cunzhong, Kong, Beihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948190/
https://www.ncbi.nlm.nih.gov/pubmed/35332131
http://dx.doi.org/10.1038/s41419-022-04670-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948190/
https://www.ncbi.nlm.nih.gov/pubmed/35332131
http://dx.doi.org/10.1038/s41419-022-04670-7

Ejemplares similares